The Filing Desk

Bioventus vs Novocure

Bioventus BVS · Novocure NVCR · Health Care Equipment

Novocure reported revenue of $655 million in fiscal 2025, 1.2 times Bioventus' $568 million in fiscal 2025. Bioventus' revenue fell 0.9% in its latest year, and Novocure's grew 8.3%. Bioventus had an operating margin of 9.5%, against -23.5% at Novocure. Free cash flow was $72 million at Bioventus and −$76 million at Novocure.

Side by side

BioventusNovocure
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$568M$655M
Revenue growth−0.9%8.3%
Revenue growth a year, last 5 years12.1%5.8%
Gross margin68.3%74.5%
Operating margin9.5%−23.5%
Net margin4.0%−20.8%
Free cash flow$72M−$76M
Free cash flow margin12.7%−11.6%
Return on capital11.1%−33.0%
Net debt to EBITDA2.5x—
Dividends and buybacks$0M$0M
Change in diluted share count6.8%3.4%
Last close$10.66$11.83
P/E at the last close13.3×—
Insider trades, last 12 months—sold $2.9 million
Piotroski F-score8 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BioventusNovocure
Operating margin
Percent of revenue
BioventusNovocure
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioventusNovocure

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bioventus and Novocure pages.